{"id":687166,"date":"2024-02-07T16:38:02","date_gmt":"2024-02-07T16:38:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=687166"},"modified":"2024-02-07T16:38:02","modified_gmt":"2024-02-07T16:38:02","slug":"allecras-cefepimeenmetazobactam-market-size-expected-to-increase-many-folds-by-2032-report-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/allecras-cefepimeenmetazobactam-market-size-expected-to-increase-many-folds-by-2032-report-delveinsight_687166.html","title":{"rendered":"Allecra\u2019s Cefepime\/enmetazobactam market size expected to increase many folds by 2032, report DelveInsight"},"content":{"rendered":"
\n
\"Allecra’s<\/a><\/div>\n
\n
Cefepime\/enmetazobactam Drug Market Forecast and Analysis<\/div>\n<\/div>\n<\/div>\n
\u201cCefepime\/enmetazobactam Market Size, Forecast, and Emerging Insight 2032\u201d report provides comprehensive insights about cefepime\/enmetazobactam for complicated urinary tract infection in the 7MM. A detailed picture of the cefepime\/enmetazobactam for cUTI in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019-32 is provided in this report along with a detailed description of the cefepime\/enmetazobactam for cUTI.<\/div>\n

DelveInsight has recently published a report on “Cefepime\/enmetazobactam Market Forecast Report<\/a><\/strong>” providing an in-depth analysis of the Cefepime\/enmetazobactam market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Cefepime\/enmetazobactam market potential and market share analysis in the Complicated Urinary Tract Infections therapeutics space across the 7MM from 2019 to 2032. <\/p>\n

The report also helps you to understand the Cefepime\/enmetazobactam clinical and commercial developments along with parameters like the drug’s Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.<\/p>\n

Interested in finding out the projected market size of Cefepime\/enmetazobactam by 2032? Visit:Cefepime\/enmetazobactam Market Forecast<\/a><\/strong><\/p>\n

Cefepime\/enmetazobactam Drug Summary<\/strong><\/p>\n

The combination of enmetazobactam and the fourth-generation cephalosporin, cefepime, aims to present an innovative therapeutic solution against a significant medical challenge. This combination has exhibited potent in vitro activity against clinical isolates of Enterobacterales, including those producing ESBL. Allecra Therapeutics is actively developing enmetazobactam, a novel β-lactamase inhibitor that effectively targets Class A serine β-lactamases, particularly ESBL. Derived from tazobactam, enmetazobactam boasts notable distinctions, indicating a potential for increased potency. Notably, it features a strategically positioned methyl group that enhances interactions with ESBL at the active site. Additionally, its zwitterionic structure facilitates improved penetration into the periplasmic space, the location of β-lactamases. Moreover, enmetazobactam demonstrates an extended half-life compared to tazobactam.<\/p>\n

In February 2020, the cefepime\/enmetazobactam combination successfully concluded a pivotal Phase III trial, showing promise for the potential treatment of urinary tract infections.<\/p>\n

Stay ahead of the competition by leveraging key insights and evolving trends in the Cefepime\/enmetazobactam Market @ Cefepime\/enmetazobactam Market Outlook and Key Assessment<\/a><\/strong><\/p>\n

Key Highlights of the Cefepime\/enmetazobactam Market Report<\/strong><\/p>\n